Catalyst Pharmaceuticals

Catalyst Pharmaceuticals EBIT

Delisted

The EBIT of Catalyst Pharmaceuticals (CPRX) as of Nov 17, 2026 is 257.78 M USD. In the previous year, EBIT was 195.12 M USD — a change of 32.11% (higher).

EBIT

257.78 MUSD

YoY

32.11%

Last updated:

In 2025, Catalyst Pharmaceuticals's EBIT was 257.78 M USD, a 32.11% increase from the 195.12 M USD EBIT recorded in the previous year.

The Catalyst Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
86.81 M USD
Jan 1, 2024
195.12 M USD
Jan 1, 2025
257.78 M USD
Jan 1, 2026 (e)
325.43 M USD
Jan 1, 2027 (e)
393.72 M USD
Jan 1, 2028 (e)
429.57 M USD
Jan 1, 2029 (e)
455.64 M USD
Jan 1, 2030 (e)
455.64 M USD
The Catalyst Pharmaceuticals EBIT history
YEAREBITYoY
est455.64 MUSD0.00%
est455.64 MUSD+6.07%
est429.57 MUSD+9.11%
est393.72 MUSD+20.98%
est325.43 MUSD+26.24%
257.78 MUSD+32.11%
195.12 MUSD+124.77%
86.81 MUSD-14.75%
101.84 MUSD+94.40%
52.39 MUSD+26.83%
41.30 MUSD+29.79%
31.82 MUSD-190.16%
-35.30 MUSD+88.95%
-18.68 MUSD-3.11%
-19.28 MUSD-5.48%
-20.40 MUSD+39.80%
-14.59 MUSD+41.50%
-10.31 MUSD+97.50%
-5.22 MUSD-14.16%
-6.08 MUSD+51.14%
-4.02 MUSD-44.69%
-7.28 MUSD-33.22%
-10.89 MUSD+116.70%
-5.03 MUSD+73.21%
-2.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Catalyst Pharmaceuticals Revenue

Catalyst Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
398.20 M USD
86.81 M USD
71.41 M USD
Jan 1, 2024
491.73 M USD
195.12 M USD
163.89 M USD
Jan 1, 2025
588.99 M USD
257.78 M USD
214.33 M USD
Jan 1, 2026 (e)
636.20 M USD
325.43 M USD
390.13 M USD
Jan 1, 2027 (e)
717.90 M USD
393.72 M USD
390.99 M USD
Jan 1, 2028 (e)
792.17 M USD
429.57 M USD
317.11 M USD
Jan 1, 2029 (e)
877.38 M USD
455.64 M USD
335.54 M USD
Jan 1, 2030 (e)
930.15 M USD
455.64 M USD
335.54 M USD

Catalyst Pharmaceuticals Margins

Catalyst Pharmaceuticals stock margins

The Catalyst Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Catalyst Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Catalyst Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
86.95 %
21.80 %
17.93 %
Jan 1, 2024
86.00 %
39.68 %
33.33 %
Jan 1, 2025
85.19 %
43.77 %
36.39 %
Jan 1, 2026 (e)
85.19 %
51.15 %
61.32 %
Jan 1, 2027 (e)
85.19 %
54.84 %
54.46 %
Jan 1, 2028 (e)
85.19 %
54.23 %
40.03 %
Jan 1, 2029 (e)
85.19 %
51.93 %
38.24 %
Jan 1, 2030 (e)
85.19 %
48.99 %
36.07 %

Catalyst Pharmaceuticals Stock analysis

What does Catalyst Pharmaceuticals do? Catalyst Pharmaceuticals Inc is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of therapies for rare diseases. The company was founded in 2002 by Dr. Gary Stevens and Steven Miller. It is headquartered in Coral Gables, Florida, and has over 70 employees. Catalyst Pharmaceuticals is listed on the NASDAQ stock exchange and has experienced rapid growth in recent years. The company aims to meet the needs of patients with rare diseases by developing innovative therapies to improve their quality of life. Catalyst Pharmaceuticals' business model is based on the discovery, development, and marketing of therapies for rare diseases that are often neglected by larger companies. The company invests in researching new treatment options and utilizes its extensive experience in drug development to create innovative medicines for rare diseases. Catalyst Pharmaceuticals' divisions include research and development, manufacturing, and sales of innovative therapies for rare diseases. The company produces a variety of drugs, including Firdapse for the treatment of Lambert-Eaton myasthenic syndrome and amifampridine for the treatment of LEMS. Catalyst Pharmaceuticals also specializes in the development of medications for nicotine addiction. Firdapse is Catalyst Pharmaceuticals' most well-known brand and is used to treat rare neurological disorders. It is an FDA-approved oral medication for LEMS, an autoimmune disease that causes severe muscle weakness. The medication acts on neuromuscular transmission and improves the release of acetylcholine in the body. Firdapse has the potential to improve the quality of life for patients with LEMS by helping them manage their daily activities. Catalyst Pharmaceuticals has also expanded its pipeline of products and is working on developing new treatment options for rare diseases. The company is expected to introduce additional products to the market in the near future, including medications for the treatment of LAMA2 deficiency, a rare genetic disorder that causes neuromuscular problems. Catalyst Pharmaceuticals' research and development department is actively involved in the discovery of new molecules and medications. Additionally, the company invests in developing new technologies to enhance the effectiveness, safety, and tolerability of medications. Overall, Catalyst Pharmaceuticals Inc is a leading company in the research and development of therapies for rare diseases. The company strives to expand its product portfolio and develop innovative solutions to improve the quality of life for patients with rare diseases. Catalyst Pharmaceuticals Inc is an example of a company that takes its responsibility to society seriously and is dedicated to the development of treatment options for rare diseases. Catalyst Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Catalyst Pharmaceuticals's EBIT

Catalyst Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Catalyst Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Catalyst Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Catalyst Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Catalyst Pharmaceuticals stock

EBIT of Catalyst Pharmaceuticals is 257.78 M USD in 2025.

EBIT of Catalyst Pharmaceuticals changed from 195.12 M USD to 257.78 M USD, representing a 32.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Catalyst Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Catalyst Pharmaceuticals historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Catalyst Pharmaceuticals

All Key Metrics — Catalyst Pharmaceuticals